Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLD Audentes Therapeutics, Inc. daily Stock Chart
BOLD [NASD]
Audentes Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.95 Insider Own1.20% Shs Outstand44.19M Perf Week-1.47%
Market Cap1.48B Forward P/E- EPS next Y-4.19 Insider Trans-16.34% Shs Float41.95M Perf Month-14.15%
Income-166.00M PEG- EPS next Q-1.08 Inst Own- Short Float4.51% Perf Quarter-10.69%
Sales- P/S- EPS this Y-28.00% Inst Trans2.55% Short Ratio3.98 Perf Half Y30.54%
Book/sh9.45 P/B3.56 EPS next Y2.80% ROA-38.10% Target Price44.92 Perf Year-0.15%
Cash/sh8.57 P/C3.92 EPS next 5Y13.20% ROE-42.20% 52W Range17.95 - 41.65 Perf YTD57.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.60% Beta-
Dividend %- Quick Ratio14.40 Sales past 5Y- Gross Margin- 52W Low84.23% ATR1.53
Employees207 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)36.13 Volatility3.97% 4.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.60% Profit Margin- Rel Volume0.50 Prev Close33.60
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume475.58K Price33.07
Recom2.10 SMA20-8.55% SMA50-10.80% SMA2002.86% Volume36,914 Change-1.58%
Apr-26-19Reiterated H.C. Wainwright Buy $44 → $48
Apr-26-19Downgrade Citigroup Neutral → Sell $28 → $32
Feb-25-19Upgrade Chardan Capital Markets Neutral → Buy $35 → $40
Jan-11-19Upgrade Guggenheim Neutral → Buy
Nov-26-18Initiated JP Morgan Overweight $35
Nov-07-18Reiterated B. Riley FBR Sell $20 → $21
Nov-07-18Downgrade William Blair Outperform → Mkt Perform
Oct-12-18Reiterated H.C. Wainwright Buy $33 → $29
Oct-10-18Initiated Guggenheim Neutral
Sep-07-18Initiated Cowen Sell $20
Sep-07-18Initiated B. Riley FBR Sell $20
Aug-21-18Initiated Citigroup Neutral $40
Jun-26-18Initiated Chardan Capital Markets Neutral $35
Feb-13-18Initiated Mizuho Neutral $26
Dec-20-17Initiated H.C. Wainwright Buy $37
Oct-17-17Initiated William Blair Outperform
Oct-16-17Downgrade Evercore ISI Outperform → In-line
Oct-12-17Initiated Raymond James Mkt Perform
Aug-17-17Initiated Evercore ISI Outperform $23
May-01-17Initiated Leerink Partners Outperform
Aug-20-19 12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 08:58AM  Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-09-19 01:32PM  Edited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 11:24PM  Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call Transcript Motley Fool
04:01PM  Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
Aug-01-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Jul-30-19 08:00AM  Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019 PR Newswire
Jul-19-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-09-19 09:56AM  How Does Investing In Audentes Therapeutics, Inc. (NASDAQ:BOLD) Impact The Volatility Of Your Portfolio? Simply Wall St.
Jun-19-19 10:41AM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Jun-07-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +6.68%
May-29-19 04:01PM  Audentes Therapeutics Announces Changes to Senior Management Team PR Newswire
May-15-19 04:45AM  Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 09:23AM  Audentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript Motley Fool
08:00AM  Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-07-19 04:32PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 01:53PM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
May-01-19 02:15PM  Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy PR Newswire
Apr-30-19 08:00AM  Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019 PR Newswire
Apr-26-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-23-19 08:00AM  Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility PR Newswire
Apr-22-19 02:39PM  Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD) Simply Wall St.
Apr-15-19 04:01PM  Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy PR Newswire
Apr-05-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-01-19 08:00AM  Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer PR Newswire
Mar-29-19 07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex New Research Emphasizes Economic Growth GlobeNewswire
Mar-18-19 04:20PM  Spark Unlikely To Get A Better Bid But These Stocks Could Be In Play Investor's Business Daily
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-08-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11:27AM  Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year Simply Wall St.
Mar-07-19 09:07AM  Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know Zacks
Mar-03-19 10:28PM  Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-19 01:48PM  Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-28-19 08:00AM  Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases PR Newswire +10.26%
Feb-27-19 09:24PM  Audentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call Transcript Motley Fool -6.28%
04:01PM  Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update PR Newswire
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
Feb-21-19 08:00AM  Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019 PR Newswire
Feb-20-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Feb-13-19 08:20AM  Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners Future Expectations, Projections Moving into 2019 GlobeNewswire
Feb-08-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-31-19 08:00AM  Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation PR Newswire
Jan-07-19 08:00AM  Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities PR Newswire +6.63%
Jan-04-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-03-19 08:00AM  Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer PR Newswire
Jan-02-19 08:00AM  Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-18 10:11AM  Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares Simply Wall St.
Dec-18-18 01:33AM  Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds? Insider Monkey -5.70%
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-07-18 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-19-18 09:51PM  Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-09-18 08:55AM  Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire -18.03%
Nov-06-18 04:21PM  Audentes Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
Nov-05-18 08:00AM  Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman PR Newswire
Oct-30-18 08:00AM  Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018 PR Newswire
Oct-16-18 07:36AM  Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-10-18 08:30PM  Audentes Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -18.73%
07:56AM  The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares Benzinga
Oct-09-18 04:20PM  Audentes Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Oct-08-18 02:50PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals
10:07AM  Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7% Zacks
Oct-05-18 05:20PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals +7.01%
08:01AM  Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society PR Newswire
08:00AM  Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society PR Newswire
Sep-26-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Sep-24-18 08:00AM  Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society PR Newswire
Sep-06-18 02:17PM  Edited Transcript of BOLD earnings conference call or presentation 7-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Aug-21-18 08:00AM  Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Aug-17-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 08:00AM  Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-08-18 03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals +5.94%
11:41AM  Mizuho Upgrades Audentes On Promising Gene Therapy Candidate Benzinga
Aug-07-18 06:25AM  Audentes Therapeutics: 2Q Earnings Snapshot Associated Press -9.82%
06:00AM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:00AM  Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Jul-31-18 08:00AM  Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Jul-20-18 09:30AM  Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-26-18 07:10AM  Free Technical Reports on Array BioPharma and Three Additional Biotech Equities ACCESSWIRE
Jun-05-18 08:00AM  Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy PR Newswire
May-31-18 08:25AM  Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment Communities, MDC Partners, and Hexcel Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-29-18 08:00AM  Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-28-18 08:02AM  Edited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE -7.61%
May-16-18 11:30AM  Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy PR Newswire
May-10-18 07:25AM  Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP ACCESSWIRE -9.05%
May-09-18 04:43PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
11:23AM  What Should We Expect From Audentes Therapeutics Incs (NASDAQ:BOLD) Earnings In The Next Couple Of Years? Simply Wall St.
08:00AM  Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 PR Newswire
May-08-18 08:00AM  Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer PR Newswire
May-02-18 08:00AM  Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018 PR Newswire
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Matthew RChief Executive OfficerAug 12Option Exercise9.5020,000190,000135,368Aug 14 07:03 PM
Patterson Matthew RChief Executive OfficerAug 12Sale34.0420,000680,835115,368Aug 14 07:03 PM
LANGE LOUIS GDirectorJun 24Sale38.201,00038,20115,678Jun 26 04:07 PM
LANGE LOUIS GDirectorJun 24Sale37.7720,000755,413285,799Jun 26 04:07 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Option Exercise0.7910,0007,90028,236May 15 04:42 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Sale36.9810,000369,79818,236May 15 04:42 PM
LANGE LOUIS GDirectorMar 25Sale35.981,55856,0580Mar 27 05:03 PM
LANGE LOUIS GDirectorMar 25Sale36.0020,000720,015305,799Mar 27 05:03 PM
Patterson Matthew RChief Executive OfficerFeb 25Option Exercise1.0521,00022,020135,700Feb 27 04:31 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Option Exercise0.7910,0007,90028,236Feb 27 04:32 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Sale30.0610,000300,55318,236Feb 27 04:32 PM
Patterson Matthew RChief Executive OfficerFeb 25Sale30.0021,000630,000118,700Feb 27 04:31 PM
Holles Natalie C.President and COOJan 24Option Exercise2.768,30022,94933,390Jan 25 07:28 PM
LANGE LOUIS GDirectorDec 24Sale18.5312,000222,365558Dec 27 05:43 PM
LANGE LOUIS GDirectorDec 24Sale18.6720,000373,434325,799Dec 27 05:43 PM
Patterson Matthew RChief Executive OfficerDec 06Option Exercise0.7840,00031,20055,000Dec 10 04:39 PM
LANGE LOUIS GDirectorNov 15Sale22.494,00089,9603,555Nov 16 06:34 PM
LANGE LOUIS GDirectorNov 15Sale22.4920,000449,800345,799Nov 16 06:34 PM
Patterson Matthew RChief Executive OfficerOct 01Option Exercise0.7821,00016,38023,078Oct 02 07:04 PM
PRASAD SUYASHSenior VP & Chief Med OfficerOct 01Option Exercise0.7910,0007,9004,699Oct 02 07:05 PM
PRASAD SUYASHSenior VP & Chief Med OfficerOct 01Sale36.8810,000368,7880Oct 02 07:05 PM
Patterson Matthew RChief Executive OfficerOct 01Sale38.1621,000801,37215,000Oct 02 07:04 PM
GRAY JOHN T.SVP, Chief Scientific OfficerSep 28Option Exercise1.05879187Oct 02 07:03 PM
GRAY JOHN T.SVP, Chief Scientific OfficerSep 28Sale40.00873,4800Oct 02 07:03 PM
Patterson Matthew RChief Executive OfficerSep 24Option Exercise0.7815,00011,70015,000Sep 24 06:12 PM
LANGE LOUIS GDirectorSep 24Sale37.4113,000486,3191,558Sep 26 07:00 PM
LANGE LOUIS GDirectorSep 24Sale37.3520,000747,061365,799Sep 26 07:00 PM
Patterson Matthew RChief Executive OfficerSep 18Option Exercise2.1912,95228,36512,952Sep 20 07:01 PM
Patterson Matthew RChief Executive OfficerSep 18Sale40.0012,952518,0800Sep 20 07:01 PM